The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial

Cancer

Volumn 100, Issue 11, 2004, Pages 2292-2299

  Wefel, Jeffrey S ^a   Lenzi, Renato ^a   Theriault, Richard L ^a   Davis, Robert N ^b   Meyers, Christina A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b The College of New Jersey   (United States)

Author keywords

Breast neoplasms; Cognition disorders; Drug therapy; Systemic chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADULT; ARTICLE; ATTENTION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LEARNING; LONGITUDINAL STUDY; NEUROPSYCHOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF REPORT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 2442649323     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20272     Document Type: Article

References (24)

1. Andersen BL. Psychological interventions for cancer patients to enhance the quality of life. J Consult Clin Psychol. 1992;60:552-568.
2. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-493.
3. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695-2701.
4. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative chemotherapy for breast carcinoma. Cancer. 1999;85:640-650.
5. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175-4183.
6. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210-218.
7. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61-66.
8. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967-982.
9. Wefel JS, Lenzi R, Theriault R, Buzder AU, Cruickshark S, Meyers CA. "Chemobrain" in breast cancer? A prologue. Cancer. In press.
10. Wechsler D. Wechsler adult intelligence scale-revised. San Antonio: The Psychological Corporation, 1981.
11. Reitan RM, Davison LA. Clinical neuropsychology: current status and applications. New York: Hemisphere Publishing Corporation, 1974.
12. Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol. 1985;7:251-263.
13. Fletcher JM. Memory for verbal and nonverbal stimuli in learning disabled subgroups: analysis by selective reminding. J Exp Child Psychol. 1985;40:244-259.
14. Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City: AJA Associates, 1983.
15. DeFilippis NA, McCampbell E, Rogers P. Development of a booklet form of the Category Test: normative and validity data. J Clin Neuropsychol. 1979;1:339-342.
16. Klove H. Clinical neuropsychology. Med Clin North Am. 1963;47:1647-1658.
17. Hathaway SR, McKinley JC. Minnesota multiphasic personality inventory. Minneapolis: National Computer Systems, 1970.
18. Cella DF. FACT manual. Version 3. Chicago: Rush-Presbyterian-St. Luke's Medical Center, 1996.
19. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12-19.
20. Greene RL. The MMPI-2/MMPI: an interpretive manual. Boston: Allyn and Bacon, 1991.
21. Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorooracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477-481.
22. Pirzada NA, Ali II, Dafer RM. Flourouracil-induced neurotoxicity. Ann Pharmacother. 2000;34:35-38.
23. Tuxen MK, Werner HS. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191-214.
24. Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16:328-334.